Sales of specialty products during the reporting quarter clocked $ 157 million against $ 148 million in Q1FY22 and $ 108 million in Q2FY21.
PRO Only Highlights
– Quarterly performance largely backed by improved realisations
– Medium-term triggers China plus and protectionist measures for tyre industry
– Valuations not inexpensive; but improved medium-term outlook
Sun Pharma, India’s largest pharma company (CMP: Rs 815, Market Cap: Rs 1,95,654 crore), has posted another strong quarter (Q2FY22) on the specialty products front, despite the COVID wave in the US. Sales of specialty products during the reporting quarter clocked $ 157 million against $ 148 million in Q1FY22 and $ 108 million in Q2FY21. These numbers don’t include sales from Ilumya, which is used to treat plaque psoriasis and has almost doubled on an annualised basis. To provide a perspective, the company…
